ALENDRONATE VERSUS PLACEBO FOR OSTEOPENIA IN HIV

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。A5163是一项II期、随机、双盲、安慰剂对照研究，研究双膦酸盐阿仑膦酸盐治疗HIV相关的骨密度（BMD）降低。80例受试者（每组40例，每组27例女性和13例男性）将接受为期48周的设盲研究治疗，此外还将接受钙/维生素D补充剂。本研究将检查每周一次阿仑膦酸钠对接受稳定抗逆转录病毒治疗（ART）的HIV感染受试者腰椎和髋部BMD的影响，以及每日补充钙/维生素D。该研究还将评估阿仑膦酸钠在该人群中的安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5163 is a phase II, randomized, double-blind, placebo-controlled study of the bisphosphonate alendronate for the treatment of HIV-associated decreased bone mineral density (BMD). 80 subjects (40 per arm, 27 female and 13 male in each) will receive blinded study treatment for 48 weeks, in addition to a calcium/vitamin D supplement. This study will examine the effect of weekly alendronate on lumbar spine and hip BMD in HIV-infected subjects receiving stable antiretroviral therapy (ART), in addition to daily calcium/vitamin D supplement. The study also will assess the safety and tolerability of alendronate in this population.